Skip to main content

Zentalis Pharmaceuticals, Inc.

ZNTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001725160

In the last 90 days, Zentalis Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 114 institutions reported holding it in 13F filings for Q2 2026, worth $228.9M in total; no superinvestor holds it.

Superinvestors holding ZNTL, Q2 2026

See all superinvestors

No superinvestor reported holding ZNTL in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of ZNTL each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q3 2022

    0 superinvestors holding at quarter end

    Sold out
    Viking Global Investors
  2. Q1 2022

    1 superinvestor holding at quarter end

    Reduced
    Viking Global Investors (−4.3%)
  3. Q3 2021

    1 superinvestor holding at quarter end

    Reduced
    Viking Global Investors (−11.7%)